Neisseria Meningitidis Clinical Trial
Official title:
Neisseria Meningitidis Burden of Disease
This study aims to provide an estimate of the proportion of suspected cases of bacterial meningitis that are due to N. meningitidis and the serogroup responsible in The Philippines and Vietnam.
n/a
Observational Model: Case-Only, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01218451 -
NeisVac-C Single Prime Study in Infants
|
Phase 3 | |
| Completed |
NCT00323050 -
Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects
|
Phase 3 | |
| Completed |
NCT01090453 -
Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants
|
Phase 2 | |
| Completed |
NCT00454987 -
Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine
|
Phase 4 | |
| Completed |
NCT00891176 -
Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines
|
Phase 3 | |
| Completed |
NCT01839188 -
Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)
|
Phase 3 | |
| Completed |
NCT01553279 -
Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)
|
Phase 3 | |
| Completed |
NCT00263653 -
Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197
|
Phase 3 | |
| Completed |
NCT00772070 -
Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine
|
Phase 2 | |
| Completed |
NCT00127855 -
Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine
|
Phase 2 | |
| Completed |
NCT00129116 -
3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age
|
Phase 2 | |
| Completed |
NCT00871338 -
Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants
|
Phase 2 | |
| Completed |
NCT00700635 -
Dose Comparison Study of Menactra® in US Children
|
Phase 2 | |
| Completed |
NCT00326118 -
Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.
|
Phase 3 | |
| Completed |
NCT00197795 -
Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults
|
Phase 2 | |
| Completed |
NCT00289783 -
Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine
|
Phase 3 | |
| Completed |
NCT00444951 -
Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia
|
Phase 3 | |
| Completed |
NCT00258700 -
Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine
|
Phase 3 | |
| Completed |
NCT03419533 -
Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers
|
||
| Completed |
NCT01978093 -
Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
|
Phase 3 |